In This Issue:
- Diversity In Clinical Trials: The Need For Diversity To Ensure Safety And Efficacy
- Federal Removal Statutes: A Review Of The Federal Courts Jurisdiction And Venue Clarification Act Of 2011
- Communication With Your PR Firm: Endangering The Attorney-Client Privilege
- Excerpt from Forward:
We seek to make Pro Te: Solutio relevant to concerns pharmaceutical and medical device companies deal with every day, from seemingly simple inter office communications to the more complicated work of developing clinical trials.
Just typing on an email or memorandum “Attorney-Client Privilege” or “Attorney Work Product” is not what makes a document privileged. Communication to Your Public Relations Firm: Privileged or Not? explores the basic tenets of privilege and the law as to what types of communications to your public relations firm may be privileged.
No Missing Pieces: The Importance of Diversity in Clinical Trials is a thoughtful article that explores the importance of making sure your clinical trials are medically, ethically, and legally sound by considering diversity in developing protocols for such trials.
The Federal Courts Jurisdiction and Venue Clarification Act of 2011 went into effect on January 6, 2012. Did it reach its goal of clarity? Changes to the Federal Removal Statutes: Questions Still Remain focuses on the issue. Some states have a statute of repose for bringing an action. We have explained how those statutes might be helpful to you in defending a lawsuit and have compiled them in Product Liability Statutes of Repose.
We hope this issue of Pro Te: Solutio will assist you in dealing with the various matters you face every day.
Please see full publication below for more information.